Literature DB >> 15070663

Hemochromatosis mutations in the general population: iron overload progression rate.

Rolf Vaern Andersen1, Anne Tybjaerg-Hansen, Merete Appleyard, Henrik Birgens, Børge Grønne Nordestgaard.   

Abstract

The progression rate of iron overload in hereditary hemochromatosis in individuals in the general population is unknown. We therefore examined in the general population iron overload progression rate in C282Y homozygotes. Using a cohort study of the Danish general population, The Copenhagen City Heart Study, we genotyped 9174 individuals. The 23 C282Y homozygotes identified were matched to 2 subjects each of 5 other HFE genotypes with respect to sex, age, and alcohol consumption. As a function of biologic age, transferrin saturation increased from 50% to 70% from 25 to 85 years of age and from 70% to 80% from 35 to 80 years of age in female and male C282Y homozygotes, respectively. Equivalently, ferritin levels increased from 100 to 500 microg/L and decreased from 800 to 400 microg/L in female and male C282Y homozygotes. As a function of 25 years follow-up irrespective of age, transferrin saturation and ferritin levels increased slightly in male and female C282Y homozygotes. None of the C282Y homozygotes developed clinically overt hemochromatosis. In conclusion, individuals in the general population with C282Y homozygosity at most demonstrate modest increases in transferrin saturation and ferritin levels, and clinically overt hemochromatosis is rare. Therefore, C282Y homozygotes identified during population screening, and not because of clinically overt hemochromatosis, at most need to be screened for manifestations of hemochromatosis every 10 to 20 years.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15070663     DOI: 10.1182/blood-2003-10-3564

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

Review 1.  Phenotypic expression of hereditary hemochromatosis: what have we learned from the population studies?

Authors:  Eng K Gan; Oyekoya T Ayonrinde; Debbie Trinder; John K Olynyk
Journal:  Curr Gastroenterol Rep       Date:  2010-02

Review 2.  Diabetes and hemochromatosis.

Authors:  T Creighton Mitchell; Donald A McClain
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

Review 3.  A diagnostic approach to hemochromatosis.

Authors:  Anthony S Tavill; Paul C Adams
Journal:  Can J Gastroenterol       Date:  2006-08       Impact factor: 3.522

4.  Effect of hereditary haemochromatosis genotypes and iron overload on other trace elements.

Authors:  Jeffrey M Beckett; Madeleine J Ball
Journal:  Eur J Nutr       Date:  2012-02-09       Impact factor: 5.614

Review 5.  Current applications of therapeutic phlebotomy.

Authors:  Tarek Bou Assi; Elizabeth Baz
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

6.  The global burden of iron overload.

Authors:  Marnie J Wood; Richard Skoien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2009-07-29       Impact factor: 6.047

7.  Competitive binding of Fe3+, Cr3+, and Ni2+ to transferrin.

Authors:  C Derrick Quarles; R Kenneth Marcus; Julia L Brumaghim
Journal:  J Biol Inorg Chem       Date:  2011-06-17       Impact factor: 3.358

8.  Clinical penetrance of C282Y homozygous HFE haemochromatosis.

Authors:  Enrico Rossi; Gary P Jeffrey
Journal:  Clin Biochem Rev       Date:  2004-08

Review 9.  Hereditary hemochromatosis and diabetes mellitus: implications for clinical practice.

Authors:  Kristina M Utzschneider; Kris V Kowdley
Journal:  Nat Rev Endocrinol       Date:  2010-01       Impact factor: 43.330

10.  Biological variability of transferrin saturation and unsaturated iron-binding capacity.

Authors:  Paul C Adams; David M Reboussin; Richard D Press; James C Barton; Ronald T Acton; Godfrey C Moses; Catherine Leiendecker-Foster; Gordon D McLaren; Fitzroy W Dawkins; Victor R Gordeuk; Laura Lovato; John H Eckfeldt
Journal:  Am J Med       Date:  2007-11       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.